Company
3 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
JUL 29, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval action for labeling change; does not report clinical trial outcomes or comparative efficacy data.
JUL 29, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for labeling change to CellCept (mycophenolate mofetil); this is a regulatory action, not a clinical trial, and does not report efficacy or safety trial outcomes.
JUL 29, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
This is an FDA supplemental approval action for a labeling change to an established immunosuppressant; it does not report clinical trial outcomes or comparative efficacy.